Johnson, M. L., Rodon, J., Aljumaily, R., Villalona-Calero, M., Borazanci, E., Pishvaian, M., Turk, A., Carvajal, R. D., Mantia, C., Giaccone, G., Mounir, Z., Patel, A., Maurer, M., Neilan, C., Rajendran, D., Ganesan, U., Hinkle, J., & Tolcher, A. W. (2022). 492TiP A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion. Annals of Oncology, 33, S766–S767. https://doi.org/10.1016/j.annonc.2022.07.620